semaglutide and chronic kidney disease in patients with overweight or obesity without diabetes: a randomized double-blind placebo-controlled clinical trial Semaglutide, Chronic Kidney Disease, and

The specific, intense desire for certain foods, particularly carbohydrate-heavy and sugar-heavy options, diminishes

According to the financial reports by Novo Nordisk, the business revenue of GLP-1 RAs has reached 34,653 million Danish krone (DKK) in the first quarter of 2023 ( The FDA Adverse Event Reporting System (FAERS) is a robust pharmacovigilance database that contains real-world data on AE reporting ( Methods Data sources FAERS is an openly accessible pharmacovigilance database documenting AEs, medication errors, and product quality complaints reported spontaneously by people of diverse occupations worldwide ( Data extraction In order to acquire AE reports data treated with GLP-1 RAs, we identified the AEs of GLP-1 RAs in the DRUG files using the generic and brand names of the FDA-approved GLP-1 RAs, specifically exenatide (BYETTA, BYDUREON), liraglutide (VICTOZA, SAXENDA), lixisenatide (ADLYXIN, SOLIQUA), dulaglutide (TRULICITY), semaglutide (OZEMPIC, RYBELSUS, WEGOVY), and tirzepatide (MOUNJARO)

En septiembre pasado, la OMS incluy los GLP-1 en su lista de medicamentos esenciales para fortalecer su acceso y pidi la produccin de versiones genricas asequibles destinadas especialmente a naciones en desarrollo

Oral semaglutide reduces the risk of MACE in high-risk patients with T2DM